Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucie Oberic

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 26, 2020
Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphomaLucie Oberic, Faustine Delzor, Caroline Protin, et al.
Radiation Oncology (London, England)|September 28, 2011
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survivalLucie Oberic, Frédéric Viret, Charlotte Baey, et al.
The Oncologist|August 18, 2009
Cancer awareness in atypical thrombotic microangiopathiesLucie Oberic, Marc Buffet, Mickael Schwarzinger, et al.
Case Reports in Hematology|June 8, 2026
Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case ReportMehdi Loukhnati, Benjamin Hebraud, Marine Cazaux, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumoursMarco Gizzi, Lucie Oberic, Christophe Massard, et al.
Journal of Hematology & Oncology|September 19, 2024
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patientsMarion Alcantara, Marion Chevrier, Fabrice Jardin, et al.
Oncotarget|November 17, 2016
Therapy-related acute myeloid leukemia following treatment of lymphoid malignanciesSarah Bertoli, Arthur Sterin, Suzanne Tavitian, et al.
Haematologica|February 17, 2022
Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphomaLouise Bouard, Benoit Tessoulin, Catherine Thieblemont, et al.
Leukemia & Lymphoma|November 12, 2020
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patientsChloé Medrano, Lucie Oberic, Florent Puisset, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2014
PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphomaMarion Alcantara, Jehan Dupuis, Sylvain Mareschal, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 26, 2020
Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphomaLucie Oberic, Faustine Delzor, Caroline Protin, et al.
Radiation Oncology (London, England)|September 28, 2011
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survivalLucie Oberic, Frédéric Viret, Charlotte Baey, et al.
The Oncologist|August 18, 2009
Cancer awareness in atypical thrombotic microangiopathiesLucie Oberic, Marc Buffet, Mickael Schwarzinger, et al.
Case Reports in Hematology|June 8, 2026
Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case ReportMehdi Loukhnati, Benjamin Hebraud, Marine Cazaux, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumoursMarco Gizzi, Lucie Oberic, Christophe Massard, et al.
Journal of Hematology & Oncology|September 19, 2024
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patientsMarion Alcantara, Marion Chevrier, Fabrice Jardin, et al.
Oncotarget|November 17, 2016
Therapy-related acute myeloid leukemia following treatment of lymphoid malignanciesSarah Bertoli, Arthur Sterin, Suzanne Tavitian, et al.
Haematologica|February 17, 2022
Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphomaLouise Bouard, Benoit Tessoulin, Catherine Thieblemont, et al.
Leukemia & Lymphoma|November 12, 2020
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patientsChloé Medrano, Lucie Oberic, Florent Puisset, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2014
PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphomaMarion Alcantara, Jehan Dupuis, Sylvain Mareschal, et al.
Pageof 7